US interchangeability requirements would be waived for US Food and Drug Administration-approved biosimilar insulins under the Biosimilar Insulin Access Bill that has just been introduced by US representative Glenn Grothman.
US Bill Urges Automatic Insulin Interchangeability
Representative Glenn Grothman Introduces Biosimilar Insulin Access Bill
A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.
